JPS6256843B2 - - Google Patents

Info

Publication number
JPS6256843B2
JPS6256843B2 JP54084681A JP8468179A JPS6256843B2 JP S6256843 B2 JPS6256843 B2 JP S6256843B2 JP 54084681 A JP54084681 A JP 54084681A JP 8468179 A JP8468179 A JP 8468179A JP S6256843 B2 JPS6256843 B2 JP S6256843B2
Authority
JP
Japan
Prior art keywords
acid
strain
lipopolysaccharide
mycobacterium tuberculosis
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54084681A
Other languages
English (en)
Japanese (ja)
Other versions
JPS568320A (en
Inventor
Chisato Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP8468179A priority Critical patent/JPS568320A/ja
Priority to US06/147,127 priority patent/US4329452A/en
Priority to FR8012794A priority patent/FR2484258A1/fr
Priority to ES493061A priority patent/ES493061A0/es
Priority to SU802943651A priority patent/SU1232124A3/ru
Priority to IT23219/80A priority patent/IT1132168B/it
Priority to CH5128/80A priority patent/CH650799A5/de
Priority to CA355,290A priority patent/CA1132047A/en
Publication of JPS568320A publication Critical patent/JPS568320A/ja
Priority to US06/293,999 priority patent/US4394502A/en
Publication of JPS6256843B2 publication Critical patent/JPS6256843B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP8468179A 1979-07-04 1979-07-04 Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent Granted JPS568320A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP8468179A JPS568320A (en) 1979-07-04 1979-07-04 Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
US06/147,127 US4329452A (en) 1979-07-04 1980-05-06 Immunotherapeutic agent for tumors comprising lipopolysaccharide as an active component
FR8012794A FR2484258A1 (fr) 1979-07-04 1980-06-09 Agent immunotherapique pour tumeurs, avec du lipopolysaccharide comme composant actif, et procede de preparation de cet agent
IT23219/80A IT1132168B (it) 1979-07-04 1980-07-03 Agente immunoterapeutico per tumori comprendente lipopolisaccaride come un componente attivo
SU802943651A SU1232124A3 (ru) 1979-07-04 1980-07-03 Способ получени липоарабиноманнана,обладающего противоопухолевой активностью
ES493061A ES493061A0 (es) 1979-07-04 1980-07-03 Un procedimiento para preparar un lipopolisacarido
CH5128/80A CH650799A5 (de) 1979-07-04 1980-07-03 Verfahren zur herstellung von lipopolysacchariden mit antitumoraktivitaet und immunotherapeutische mittel gegen tumore.
CA355,290A CA1132047A (en) 1979-07-04 1980-07-03 Immunotherapeutic agent for tumors comprising lipopolysaccharide as an active component
US06/293,999 US4394502A (en) 1979-07-04 1981-08-18 Immunotherapeutic agent for tumors comprising lipopolysaccharide as an active component

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8468179A JPS568320A (en) 1979-07-04 1979-07-04 Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent

Publications (2)

Publication Number Publication Date
JPS568320A JPS568320A (en) 1981-01-28
JPS6256843B2 true JPS6256843B2 (enExample) 1987-11-27

Family

ID=13837428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8468179A Granted JPS568320A (en) 1979-07-04 1979-07-04 Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent

Country Status (8)

Country Link
US (2) US4329452A (enExample)
JP (1) JPS568320A (enExample)
CA (1) CA1132047A (enExample)
CH (1) CH650799A5 (enExample)
ES (1) ES493061A0 (enExample)
FR (1) FR2484258A1 (enExample)
IT (1) IT1132168B (enExample)
SU (1) SU1232124A3 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5718619A (en) * 1980-07-10 1982-01-30 Chisato Maruyama Tumor immunotherapy agent containing lipopolysaccharide as active principle
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法
US4612304A (en) * 1985-06-11 1986-09-16 Ss Pharmaceutical Co., Ltd. Antitumor formulation containing lipopolysaccharide with trehalose derivatives
US4818751A (en) * 1985-07-02 1989-04-04 Zeria Shinyaku Kogyo Kabushiki Kaisha Cosmetics
EP0295749A1 (en) * 1987-06-15 1988-12-21 Duphar International Research B.V Sulpholipopolysaccharides as stimulators of the non-specific defence mechanism
US4798369A (en) * 1987-11-03 1989-01-17 The Firestone Tire & Rubber Company Ultrasonic air spring system
US5853737A (en) * 1992-12-10 1998-12-29 Brigham And Women's Hospital Method for inducing a CD1-restricted immune response
US6238676B1 (en) * 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5712123A (en) * 1994-10-07 1998-01-27 Board Of Trustees Of The University Of Illinois Mixture having antitumor activities
WO1998056941A1 (en) * 1995-12-12 1998-12-17 Tai Ho Chung Carbohydrate complex extracted from mycobacterium tuberculosis and process for the preparation thereof
US5869645A (en) * 1997-10-15 1999-02-09 Board Of Trustees Of The University Of Illinois Method for isolating high molecular weight antineoplastic glycans using urea
NZ505538A (en) * 2000-07-03 2004-12-24 Malaghan Inst Of Medical Res A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
PL1765391T3 (pl) * 2004-06-07 2013-08-30 Qu Biologics Inc Kompozycje bakteryjne do leczenia nowotworów
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
JP2015157763A (ja) * 2012-05-28 2015-09-03 エヌエーアイ株式会社 認知症の治療剤及び予防剤
EP3125763A4 (en) 2014-03-31 2017-12-13 University of Utah Research Foundation Fluid analysis device and associated systems and methods
CA3254723A1 (en) 2014-05-02 2025-04-15 Qu Biologics Inc ANTIMICROBIAL IMMUNOMODULATION
EP4226939A4 (en) * 2020-10-09 2024-11-13 Zeria Pharmaceutical Co., Ltd. NEW USE OF A MYCOBACTERIUM TUBERCULOSIS EXTRACT

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1188519A (en) * 1966-10-27 1970-04-15 Wellcome Found Method for the Purification of Lipopolysaccharides
NL7308450A (enExample) * 1972-06-20 1973-12-27
FR2227862A1 (en) * 1973-05-04 1974-11-29 Anvar Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues
JPS5132794A (en) * 1974-06-20 1976-03-19 Anvar Koshuyokoirusu oyobi ajubantokatsuseiojusuru maikobakuteriumufurakushonnoseiseiho

Also Published As

Publication number Publication date
CH650799A5 (de) 1985-08-15
ES8105783A1 (es) 1981-06-16
US4329452A (en) 1982-05-11
JPS568320A (en) 1981-01-28
IT8023219A0 (it) 1980-07-03
CA1132047A (en) 1982-09-21
US4394502A (en) 1983-07-19
FR2484258A1 (fr) 1981-12-18
ES493061A0 (es) 1981-06-16
SU1232124A3 (ru) 1986-05-15
FR2484258B1 (enExample) 1984-11-30
IT1132168B (it) 1986-06-25

Similar Documents

Publication Publication Date Title
JPS6256843B2 (enExample)
JP3717511B2 (ja) サポニン−抗原複合物とその用途
Strandberg et al. Purification and Properties of the Slow Reacting Substance Formed in the Cat Paw Perfused with Compound 48/80 1
JPH04503363A (ja) 新規リピドａ誘導体およびその用途
Azuma et al. Fractionation of mycobacterial cell wall. Isolation of arabinose mycolate and arabinogalactan from cell wall fraction of Mycobacterium tuberculosis strain Aoyama B
Paulsen et al. Structural studies of the polysaccharide from Aloe plicatilis Miller
DMIITRIEV et al. Somatic Antigens of Pseudomonas aeruginosa: The Structure of the Polysaccharide Chain of Ps. aeruginosa O‐Serogroup 7 (Lanyi) Lipopolysaccharide
JPS6399091A (ja) Ｏ−α−グリコシドおよびその製法
CN118126210B (zh) 一种菜豆种子均一多糖及其制备方法和应用
Adams et al. Studies on the chemical constitution of cell-wall lipopolysaccharides from Neisseria perflava
AU4883100A (en) Galactopyranosides and their use
Etzler et al. Immunochemical studies on blood groups: XLVI. Oligosaccharides isolated after hydrolysis of hog gastric mucin blood group A+ H substance previously treated with the blood group de-N-acetylating enzyme
McKibbin et al. Characterization of dog small intestinal fucolipids with human blood group A activity. Differences in dog and human A-active fucolipids
Zdebska et al. Studies on the Structure and I‐Blood‐Group Activity of Poly (glycosyl) ceramides
Li et al. Efficient synthesis of α-galactosylceramide and its C-6 modified analogs
Flowers Substituted cerebrosides: Part II. Synthetic dihydrosulfatides
CN118791643A (zh) 桔梗均一多糖及其制备方法和应用
Halkes et al. Synthesis of the spacer-containing β-D-GalpNAc-(1→ 4)-β-D-GlcpNAc-(1→ 3)-α-D-Galp moiety, representing the non-fucosylated backbone trisaccharide of the glycocalyx glycan of the parasite Schistosoma mansoni
Gorshkova et al. Structural studies of O-specific polysaccharide chains of the lipopolysaccharide from Yersinia enterocolitica serovar O: 10
de Lederkremer et al. Convenient syntheses of 5-O-and 3, 5-di-O-(β-d-galactofuranosyl)-d-galactofuranose
Lahmann et al. Synthesis of the Lewis b hexasaccharide and HSA-conjugates thereof
US4794176A (en) Synthesis of tumor antigenic determinant
US4973581A (en) Glucan derivatives having tumoricidal activity
Bhakoo et al. Isolation and characterization of a novel monoacylated glucopyranosyl neutral lipid from the plasma membrane of Acholeplasma laidlawii B
Jagtap et al. Extraction, structural characterization, and bioactivity of laminarin and fucoidan from brown macroalgae Chorda filum